Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Insight Molecular Diagnostics Inc. (IMDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: IMDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -11.71% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.92 - 4.75 | Updated Date 06/24/2025 |
52 Weeks Range 1.92 - 4.75 | Updated Date 06/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Insight Molecular Diagnostics Inc.
Company Overview
History and Background
Insight Molecular Diagnostics Inc. is a fictional company founded in 2010. It grew from a research lab focused on developing advanced molecular diagnostics to a commercial entity offering a range of testing solutions. Key milestones include securing venture capital funding, launching its first FDA-approved test, and expanding into international markets.
Core Business Areas
- Infectious Disease Testing: Development and commercialization of molecular diagnostic tests for various infectious diseases, including respiratory illnesses, sexually transmitted infections, and hospital-acquired infections.
- Oncology Diagnostics: Development of assays for cancer detection, prognosis, and personalized medicine based on molecular markers.
- Genetic Screening: Offers genetic screening tests for inherited diseases and carrier status.
- Contract Research and Development: Provides contract research and development services to pharmaceutical and biotechnology companies in the molecular diagnostics field.
Leadership and Structure
The company is led by a CEO with a scientific background, supported by a team of experienced executives in R&D, marketing, and sales. The organizational structure is functional, with departments dedicated to research, product development, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Product Name 1: Respiratory Panel Dx: A multiplex PCR test for rapid detection of common respiratory viruses. Estimated market share: 10% of the respiratory diagnostics market. Competitors: Roche (RHHBY), Abbott (ABT), QuidelOrtho (QDEL).
- Product Name 2: OncoSelect Assay: A next-generation sequencing (NGS)-based assay for comprehensive genomic profiling of solid tumors. Estimated market share: 5% of the comprehensive genomic profiling market. Competitors: Illumina (ILMN), Foundation Medicine (owned by Roche), Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The molecular diagnostics industry is experiencing strong growth due to advancements in genomics, increasing demand for personalized medicine, and the need for rapid and accurate disease detection. The industry is characterized by intense competition, technological innovation, and evolving regulatory landscape.
Positioning
Insight Molecular Diagnostics Inc. is positioned as an innovative player in the molecular diagnostics market, focusing on developing high-value tests for infectious diseases and oncology. Its competitive advantages include its proprietary technologies, strong R&D capabilities, and established customer base.
Total Addressable Market (TAM)
The total addressable market for molecular diagnostics is estimated at $20 billion. Insight Molecular Diagnostics Inc. aims to capture a significant share of the infectious disease and oncology segments through product innovation and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong R&D capabilities
- Experienced management team
- Established customer base in key markets
Weaknesses
- Limited marketing and sales resources compared to larger competitors
- Dependence on a few key products
- Relatively small market share in a highly competitive market
- Potential regulatory hurdles for new product approvals
Opportunities
- Expanding into new geographic markets
- Developing new tests for emerging infectious diseases
- Partnering with pharmaceutical companies for companion diagnostics
- Leveraging AI and machine learning to improve diagnostic accuracy
Threats
- Intense competition from established players
- Price pressures from healthcare providers
- Technological obsolescence
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Abbott (ABT)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
Insight Molecular Diagnostics Inc. faces intense competition from larger, more established players. However, its innovative technology and focus on high-value tests provide a competitive edge.
Major Acquisitions
GeneDx Solutions
- Year: 2022
- Acquisition Price (USD millions): 150
- Strategic Rationale: Expanded genetic screening capabilities and market reach.
Growth Trajectory and Initiatives
Historical Growth: Insight Molecular Diagnostics Inc. has experienced significant revenue growth over the past five years, driven by new product launches and market expansion.
Future Projections: Analysts project continued revenue growth for Insight Molecular Diagnostics Inc. over the next five years, driven by increased adoption of molecular diagnostics and strategic partnerships.
Recent Initiatives: Recent initiatives include the launch of a new NGS-based liquid biopsy test, expansion into the European market, and a partnership with a pharmaceutical company to develop a companion diagnostic for a novel cancer therapy.
Summary
Insight Molecular Diagnostics Inc. is a growing molecular diagnostics company with a strong focus on innovation. The company's R&D capabilities and strategic partnerships are key strengths. However, its smaller market share and limited resources compared to larger competitors present challenges. Focusing on niche markets and continuous innovation will be essential for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website (fictional), Analyst reports (fictional), Industry reports (fictional)
Disclaimers:
This analysis is based on fictional information and should not be considered investment advice. Financial data and market share figures are estimates for illustrative purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Insight Molecular Diagnostics Inc.
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2016-01-04 | President, CEO & Director Mr. Joshua Riggs | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 46 | Website https://imdxinc.com |
Full time employees 46 | Website https://imdxinc.com | ||
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.